PM
CLDX icon

Parametrica Management’s Celldex Therapeutics CLDX Stock Holding History

Parametrica Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-950
Closed -$223K – 107
2015
Q4 		$223K Buy
+950
New +$207K 1.47% 33

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Parametrica Management's CLDX Position: Q1 2016 in Review

Parametrica Management sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 950 shares — an estimated $223K sold.

Parametrica Management first reported a position in CLDX in Q4 2015 and held it in 1 quarter. The position peaked at $223K in Q4 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Parametrica Management reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Parametrica Management sold 950 Celldex Therapeutics shares in Q1 2016, an estimated $223K.
  • Parametrica Management first reported a position in Celldex Therapeutics in Q4 2015 and held it in 1 quarter.
  • Parametrica Management's Celldex Therapeutics position peaked at $223K in Q4 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Parametrica Management's 13F filing for Q1 2016, filed 5 May 2016.